Yusuf Hamied news from FiercePharma
News
Lancet: Glaxo HIV med boosts cardiac risk
A leading AIDS med made by GlaxoSmithKline carries nearly double the risk of heart attack compared with other anti-HIV meds, according to a new study published by the Lancet. Abacavir--which Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends